BioCryst’s antiviral candidate got a federal boost today.
The Durham-based company, which is developing an antiviral dubbed BCX4430, had already partnered with the National Institute of Allergy and Infectious Diseases, receiving an initial award of $5 million last September. As part of an amended agreement – the NIAID released an additional $1.89 million for the drug’s development. Specifically, the NIAID has teamed up with BioCryst to develop an IV formulation of the drug.
If all contract…